Tumor mutational burden, CD8+ T lymphocytes infiltration or gene expression profiles could represent alternative biomarkers of response for a better selection of individuals for specific therapies and to optimize the outcomes of this disease [8]. The gene discussed is CD8A; the disease is neoplasm.